#USA #Boston #Morphic Medical #Dr. Terri Cooper #RESET Device

Morphic Medical's New Board Appointments

Morphic Medical, known for its groundbreaking device targeting the root causes of type 2 diabetes, is making waves with its latest board appointments. Dr. Terri Cooper has been appointed Chair of the Board of Directors, alongside Craig Richardson, who joins as a Non-Executive Board Member. These strategic hires come in the wake of the company receiving CE Mark approval for its flagship product, RESET, and further solidifying its expansion into European markets while preparing for a wider international reach.

Dr. Cooper brings a wealth of experience in the healthcare sector, having successfully steered numerous organizations through dynamic growth periods. In her new role, she intends to collaborate closely with Morphic's executive team and fellow board members, focusing on enhancing corporate governance and driving long-term value creation. "Morphic Medical has developed exciting technology that has the potential to redefine treatment for obesity and metabolic diseases," Dr. Cooper stated. She expresses her eagerness to contribute to the company’s mission, especially at this critical juncture.

Craig Richardson enhances the board by introducing his comprehensive background in health economics and market access, crucial for maximizing patient access to RESET. He comments on the pressing issue that rising obesity rates and related healthcare costs present globally. "The potential of RESET to provide substantial benefits for patients while alleviating financial pressures on healthcare systems cannot be understated," he declared. Richardson is excited to support Morphic in forging essential partnerships and building robust health economic evidence to ensure broad acceptance and reimbursement for their innovative therapies.

With these strategic appointments, Morphic Medical underlines its commitment to establishing a first-rate board that aligns with their commercial ambitions and long-term goals to significantly improve health outcomes for individuals impacted by obesity and type 2 diabetes.

CEO Mike Gutteridge voiced his appreciation for outgoing Chair Mark Lerdal’s contributions during his term, highlighting the strengthened board's role in navigating the company's journey forward. "We're thrilled to welcome Dr. Cooper and Mr. Richardson as they bring invaluable insights that will bolster our efforts in demonstrating the clinical value of RESET and improving the lives of patients around the world."

Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts, and continues to innovate in the realm of metabolic health. Their pioneering approach with RESET sets an exciting precedent for future treatments, acknowledged and approved across the EU and UK markets. Although currently limited to investigational use in the U.S., the company is poised for significant breakthroughs as they prepare for healthcare landscapes globally.

As Morphic prepares for its next chapter, the leadership changes herald a robust commitment to advancing healthcare solutions for visceral challenges presented by type 2 diabetes and obesity. For further information on Morphic Medical and their innovative RESET device, visit morphicmedical.com or follow them on social media platforms like Twitter and LinkedIn.